SCHEMBL1303743

SCHEMBL1303743

FC(F)(F)c1nnc[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3842963 0.80
SCHEMBL2104853 0.74
SCHEMBL2038975 0.62
SCHEMBL12131262 0.61
SCHEMBL12173291 0.59 CSNK2A1 (0.31)
SCHEMBL2642454 0.57
Amitrole SCHEMBL1187664 0.57
SCHEMBL25335684 0.56 CYP19A1 (0.41)
SCHEMBL2161282 0.56 NPSR1 (0.33)
SCHEMBL15748053 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004069998-A2 OXINDOLE DERIVATIVES AS ANTIMICROBIAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2004-08-19 WO claimed
EP-0869785-B1 4-HYDROXYCOUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS UPJOHN CO (US) 2002-08-28 EP claimed
JP-2000500490-A 2000-01-18 JP claimed
EP-0869785-A1 4-HYDROXYCOUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF DIABETES MELLITUS PHARMACIA &amp; UPJOHN COMPANY (US) 1998-10-14 EP claimed
US-5723476-A 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus PHARMACIA & UPJOHN COMPANY (US) 1998-03-03 US claimed
WO-1997018808-A1 4-HYDROXYCOUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF DIABETES MELLITUS PHARMACIA & UPJOHN COMPANY (US) 1997-05-29 WO claimed
US-12528781-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-01-20 US disclosed
US-20260007672-A1 INHIBITORS OF MPTP NRG THERAPEUTICS LTD (GB) 2026-01-08 US disclosed
US-12491185-B2 Inhibitors of mPTP NRG THERAPEUTICS LTD (GB) 2025-12-09 US disclosed
US-12404261-B2 Compounds and compositions for treating conditions associated with cGAS NOVARTIS AG (CH) 2025-09-02 US disclosed
US-20250177397-A1 INHIBITORS OF MPTP NRG THERAPEUTICS LTD (GB) 2025-06-05 US disclosed
US-12221441-B2 Plasma kallikrein inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-11 US disclosed
CN-119343343-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2025-01-21 CN disclosed
US-20050272779-A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2005-12-08 US disclosed
WO-2005095351-A1 N1 - ((PYRAZOL-1-YMETHYL) -2-METHYLPHENYL)- PHATALAMIDE DERIVATIVES AND RELATED COMPOUNDS INSECTICIDES BAYER CROPSCIENCE AG (DE) 2005-10-13 WO disclosed
WO-2004069998-A2 OXINDOLE DERIVATIVES AS ANTIMICROBIAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2004-08-19 WO disclosed
EP-0869785-B1 4-HYDROXYCOUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS UPJOHN CO (US) 2002-08-28 EP disclosed
EP-0869785-A1 4-HYDROXYCOUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF DIABETES MELLITUS PHARMACIA &amp; UPJOHN COMPANY (US) 1998-10-14 EP disclosed
US-5723476-A 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus PHARMACIA & UPJOHN COMPANY (US) 1998-03-03 US disclosed
WO-1997018808-A1 4-HYDROXYCOUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF DIABETES MELLITUS PHARMACIA & UPJOHN COMPANY (US) 1997-05-29 WO disclosed